Apr 2, 2021
Increased overall survival compared with portal vein embolization, liver resection
In a highly select group of patients with colorectal cancer and nonresectable liver metastases, high liver tumor load, and left-sided primary tumors, liver transplant brought about significantly higher overall survival (OS) rates compared with portal vein embolization (PVE) and liver resection. Thus, liver transplant may be a viable treatment option in future prospective studies of select patients with colorectal liver metastasis, researchers reported.
Although liver resection is the standard of care in patients with colorectal cancer and liver metastasis, few patients qualify as candidates, according to researchers led by Svein Dueland, MD, PhD, of Oslo University Hospital, Norway, who had previously demonstrated significant differences in OS after liver transplant in patients with primary tumors located in the ascending colon compared with those with primary tumors in the rest of the c
Loading video.
VIDEO: Research News: Delays in lung cancer screening associated with rise in malignancy rates at a single institution view more
Credit: American College of Surgeons
CHICAGO (December 17, 2020): The current surge in coronavirus disease 2019 (COVID-19) cases poses challenges for providers and institutions in delivering care to infected patients while also placing demands on them to keep up with timely and sometimes critical care for patients with cancer, heart disease and other serious illnesses who might experience advanced complications and/or earlier death if they have lapses in their care. Reporting on how deferred care worsened outcomes for lung cancer patients when the COVID-19 pandemic first surged in the spring of 2020, researchers from the University of Cincinnati explained that they have identified a framework that could help people with serious health conditions keep up their appointments during the current surge. The study has been selected for t